Develops antibody therapeutics for patients and uses an AI drug-creation platform to support programs for biopharmaceutical partners.
10-K for FY2025, filed Mar 24, 2026We are a clinical-stage biopharmaceutical company using an AI-native approach to develop differentiated antibody therapeutics. Our…View ↗
Our strategy is to leverage our Integrated Drug Creation platform to create differentiated antibody-based therapeutics for our own pipeline…View ↗
Partnered Programs: We may enter into drug creation collaborations for drug creation programs and co-development partnerships with third…View ↗
Partners pay fees for drug-creation work upfront, when project milestones are reached, and throughout programs; future payments may also include development milestones and royalties on product sales.
10-K for FY2025, filed Mar 24, 2026Our revenue currently consists primarily of fees earned from our partners in conjunction with drug creation agreements utilizing our…View ↗
$2.8M
10-K for FY2025, filed Mar 24, 2026
$2.8M ↗
Biopharmaceutical partners engage Absci for drug-creation collaborations and co-development programs using its platform.
10-K for FY2025, filed Mar 24, 2026
No. It lost $115.2M in FY2025.
Shrinking. Revenue fell 41% in 4 years, from $4.8M in FY2021 to $2.8M in FY2025, about 13% a year.
Internal programs advance further
The older report described an internal drug-discovery pipeline alongside partner work. The latest report says Absci plans to advance selected internally developed programs through clinical development and potential commercialization, while partnering or out-licensing others.
10-K for FY2022, filed Mar 30, 2023 10-K for FY2025, filed Mar 24, 2026
A sharper focus on antibodies
The older report described a broad biologics platform that included cell-line development and new modalities. The latest report centers its platform and pipeline on antibody-based therapeutics.
10-K for FY2022, filed Mar 30, 2023 10-K for FY2025, filed Mar 24, 2026
Competes with Hope Medicine, Veradermics, Pelage Pharmaceuticals, Cosmo Pharmaceuticals, Chugai Pharmaceuticals, GenSci, Merck, Roche/Roivant, Sanofi/Teva, Spyre, AbbVie, Xencor, Generate Biomedicines, Xaira Therapeutics, Recursion Pharmaceuticals, and Isomorphic Labs
10-K for FY2025, filed Mar 24, 2026ABS-201 in AGA: Existing FDA-approved treatments for AGA include oral minoxidil, oral finasteride, oral dutasteride, and topical minoxidil…View ↗
Loading...